Case Report on Anti-Tubercular Drug Induced Hepatoxicity / Modified ATT

Published on:November 2021
Indian Journal of Pharmacy Practice, 2021; 14(4):294-297
Case Report | doi:10.5530/ijopp.14.4.59

Case Report on Anti-Tubercular Drug Induced Hepatoxicity / Modified ATT

Authors and affiliation (s):

M Saru Khan1,*, Basil Sunny2, Rithuvaren M Krishnan3

1Department of pharmacy practice, Annai JKK Sampoorani Ammal College of Pharmacy, Erirmedu, Namakkal, Tamil Nadu, INDIA.

2Basil Sunny Manager and Clinical Pharmacologist of Sun Rise Hospital, Kochi, Kerala, INDIA.

3Annai JKK sampoorani Ammal college of pharmacy, Tamil Nadu, INDIA.


This case summary focusing on a 67-year male patient admitted in Sun rise Hospital, Kochi with k/c/o active tubercular on cat.2 ATT, now patient came complaint with c/o decreased appetite, food intake, nausea, vomiting and excessive fatigability. The patient was received first line anti tubercular drugs 6 months back RHZE (Rifampin, Pyrazinamide, Ethambutol, and Isoniazid) and discontinued medication 2 months back. Now it is developed a severe hepatitis which is an adverse drug reaction of the Anti-tubercular drugs.

Keywords: Hepatitis, Adverse drug reaction of anti-TB drug, Treatment, Pulmonary Koch infection, ALT, AST, Modified att.


The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmacy Practice (IJOPP) [ISSN-0974-8326] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 2008.


IJOPP uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2014 are being assigned DOIs for its permanent URLs